The Global Premiere of Clinical trial Phase I data of recombinant human lactoferrin and Lysozyme Oral Solution (Project HY1002) September 25, 2021, the 6th “China Biomed Innovation and Investment Conference” was successfully held in Suzhou. As the star session of the conference, the Global Premiere of Clinical Data session attracted much attention from all walks of life. This year, there are n... Posted by Site editor|2021-09-26 LearnMore
Plant-derived recombinant human serum albumin as a raw material and excipient is increasingly being valued September 28th, at the Asia Biopharmaceutical Innovation Summit (BIC2021) held in Shanghai, Wuhan Healthgen Biotechnology Corp., was invited as a guest to discuss the plant-derived recombinant human serum albumin independently developed based on the rice endosperm high expression... Posted by Site editor|2021-09-29 LearnMore
Plant-derived Recombinant Human Serum Albumin Injection (HY1001 project) Clinical Trials Phase II Data Progress Report September 26th, China Health Ecology Organization (CHEO) was grandly held in Bo’ao. At the Pharmaceutical Innovation and Capital Market sub-forum of the China Pharmaceutical Innovation Ecological conference (CPIE), which is the one of the six core summits of CHEO, Professor... Posted by Site editor|2021-09-27 LearnMore
Application of plant-derived Recombinant Fibronectin in diagnose reagents Fibronectin (Fn), is mainly synthesized by liver and vascular endothelial cells, and widely found in animal plasma, body fluids and tissues. It's a large molecular glycoprotein with a molecular weight of 220-250 KD in monomer, 450 KD in dimer, and has various biological activ... Posted by Site editor|2020-02-21 LearnMore
Recombinant human serum albumin OsrHSA successfully obtained the DMF from U.S. FDA OsrHSA(excipient grade), plant-derived recombinant human serum albumin independently developed by Wuhan Healthgen Biotechnology Corp.(hereinafter referred to as Healthgen Biotech), has officially passed the US Food and Drug Administration (FDA) certification and successfully obta... Posted by Site editor|2015-12-16 LearnMore
Pre 1 2 3 4 5 Next

Wuhan Healthgen Biotechnology Corp.

Tel. +86 027 59301891 Ext 8015

Fax. +86 027 59403931

E-mail cjing@oryzogen.com

268 Shendun 5th Road, East Lake High-Tech Development Zone, Wuhan, China 430020

Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3